Recent developments in biological aspects of chalcones: the odyssey continues

References

• Kozlowski D, Trouillas P, Calliste C, et al. Density functional theory study of the conformational, electronic, and antioxidant properties of natural chalcones. J Phys Chem. 2007;111:1138–1145.
   PubMed Web of Science ®Google Scholar
• Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem. 2007;42:125–137.
   PubMed Web of Science ®Google Scholar
• Evranos Aksoz B, Ertan R. Chemical and structural properties of chalcones I. FABAD J Pharm Sci. 2011;36:223–242.
   Google Scholar
• Akihisa T, Tokuda H, Hasegawa D, et al. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J Nat Prod. 2006;69:38–42.
   PubMed Web of Science ®Google Scholar
• Mishra L, Sinha R, Itokawa H, et al. Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2’-Benzimidazolyl) pyridine/chalcone as co-ligand. Bioorg Med Chem. 2001;9:1667–1671.
   PubMed Web of Science ®Google Scholar
• Bhale PS, Chavan HV, Dongare SB, et al. Synthesis of extended conjugated indolyl chalcones as potent anti-breast cancer, anti-inflammatory and antioxidant agents. Bioorg Med Chem Lett. 2017;27:1502–1507.
   PubMed Web of Science ®Google Scholar
• Coskun D, Erkisa M, Ulukaya E, et al. Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: synthesis, characterization and anticancer activity. Eur J Med Chem. 2017;136:212–22.10.
   PubMed Web of Science ®Google Scholar
• Gomes MN, Braga RC, Grzelak EM, et al. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity. Eur J Med Chem. 2017;137:126–138.
   PubMed Web of Science ®Google Scholar
• Li J, Li D, Xu Y, et al. Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as antiinflammatory agents. Bioorg Med Chem Lett. 2017;27:602–606.
   PubMedGoogle Scholar
• Israf DA, Khaizurin TA, Syahida A, et al. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF- B nuclear translocation and I -B phosphorylation in RAW264.7 macrophage cells. Mol Immunol. 2007;44:673–679.
   PubMed Web of Science ®Google Scholar
• Gan XH, Hu DY, Wang YJ, et al. Novel trans-ferulic acid derivatives containing a chalcone moiety as potential activator for plant resistance induction. J Agric Food Chem. 2017;65:4367–4377.
   PubMed Web of Science ®Google Scholar
• Cole AL, Hossain S, Cole AM, et al. Synthesis and bioevaluation of substituted chalcones, coumaranones and other flavonoids as anti-HIV agents. Bioorg Med Chem. 2016;24:2768–2776.
   PubMed Web of Science ®Google Scholar
• Ruiz-Torres V, Encinar JA, Herranz-Lopez M, et al. An updated review on marine anticancer compounds: the use of virtual screening for the discovery of small-molecule cancer drugs. Molecules. 2017;22:1037.
   PubMed Web of Science ®Google Scholar
• Kerru N, Singh P, Koorbanally N, et al. Recent advances (2015–2016) in anticancer hybrids. Eur J Med Chem. 2017;142:179–212.
   PubMed Web of Science ®Google Scholar
• Birbrair A, Zhang T, Wang ZM, et al. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol. 2014;307:C25–38.
   PubMed Web of Science ®Google Scholar
• Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Eng J Med. 1993;329:1318–1327.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2018. Atlanta (GA): American Cancer Society; 2018.
   Google Scholar
• Shagufta A. An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. Med Chem Com. 2017;8:871–885.
   Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–475.
   PubMed Web of Science ®Google Scholar
• Brown CHJ, Lain S, Verma CHS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–873.
   PubMed Web of Science ®Google Scholar
• Bellamkonda K, Satapathy SR, Douglas D, et al. Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer. Cancer Lett. 2018;437:13–24.
   PubMed Web of Science ®Google Scholar
• Karthikeyan C, Narayana Moorthy NSH, Ramasamy S, et al. Advances in chalcones with anticancer activities. Recent Pat Anticancer Drug Discov. 2015;10:97–115.
   PubMed Web of Science ®Google Scholar
• Batovska DI, Todorova IT. Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol. 2010;5:1–29.
   PubMedGoogle Scholar
• Singh P, Anand A, Kumar V. Recent developments in biological activities of chalcones. a mini review. Eur J Med Chem. 2014;85:758–777.
   PubMed Web of Science ®Google Scholar
• Reddy MVB, Su CR, Chiou WF, et al. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents. Bioorg Med Chem. 2008;16:7358–7370.
   PubMed Web of Science ®Google Scholar
• Nagaraju M, Deepthi EG, Ashwini C, et al. Synthesis and selective cytotoxic activity of novel hybrid chalcones against prostate cancer cells. Bioorg Med Chem Lett. 2012;22:4314–4317.
   PubMed Web of Science ®Google Scholar
• Kamal A, Reddy JS, Ramaiah MJ, et al. Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents. Med Chem Commun. 2010;1:355–360.
   Google Scholar
• Tseng CH, Chen YL, Hsu CY, et al. Synthesis and antiproliferative evaluation of 3-phenylquinolinylchalcone derivatives against non-small cell lung cancers and breast cancers. Eur J Med Chem. 2013;59:274–282.
   PubMed Web of Science ®Google Scholar
• Abonia R, Insuasty D, Castillo J, et al. Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity. Eur J Med Chem. 2012;57:29–40.
   PubMed Web of Science ®Google Scholar
• Robinson MW, Overmeyer JH, Young AM, et al. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death. J Med Chem. 2012;55:1940–1956.
   PubMed Web of Science ®Google Scholar
• Mielcke TR, Mascarello A, Chiela EF, et al. Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation. Eur J Med Chem. 2012;48:255–264.
   PubMed Web of Science ®Google Scholar
• Ratkovic Z, Juranic ZD, Stanojkovic T, et al. Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg Chem. 2010;38:26–32.
   PubMed Web of Science ®Google Scholar
• Singh A, Lumb I, Mehra V, et al. Ferrocene-appended pharmacophores: an exciting approach for modulating biological potential of organic scaffolds. Dalton Trans. 2019. doi:10.1039/C8DT03440K
   Google Scholar
• Reddy POV, Hridhay M, Nikhil K, et al. Synthesis and investigations into the anticancer and antibacterial activity studies of β-carboline chalcones and their bromide salts. Bioorg Med Chem Lett. 2018;28:1278–1282.
   PubMed Web of Science ®Google Scholar
• Kuthyala S, Nagaraja GK, Sheik S, et al. Synthesis of imidazo [1, 2-a]pyridine-chalcones as potent inhibitors against A549 cell line and their crystal studies. J Mol Struc. DOI:10.1016/j.molstruc.2018.09.087.
   Web of Science ®Google Scholar
• Michelini LJ, Castro MRC, Custodio JMF, et al. A novel potential anticancer chalcone: synthesis, crystal structure and cytotoxic assay. J Mol Struc. 2018;1168:309–315.
   Web of Science ®Google Scholar
• Wang G, Qiu J, Xiao X, et al. Synthesis, biological evaluation and molecular docking studies of a new series of chalcones containing naphthalene moiety as anticancer agents. Bioorg Chem. 2018;76:249–257.
   PubMed Web of Science ®Google Scholar
• Park S, Kim EH, Kim J, et al. Biological evaluation of indolizine-chalcone hybrids as new anticancer agents. Eur J Med Chem. 2018;144:435–443.
   PubMed Web of Science ®Google Scholar
• Wang G, Peng Z, Zhang J, et al. Synthesis, biological evaluation and molecular docking studies of aminochalcone derivatives as potential anticancer agents by targeting tubulin colchicine binding site. Bioorg Chem. 2018;78:332–340.
   PubMed Web of Science ®Google Scholar
• Ayati A, Esmaeili R, Moghimi S, et al. Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents. Eur J Med Chem. 2018;145:404–412.
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Khan P, Ahmad K, et al. Synthesis, characterization and biological evaluation of tertiary sulfonamide derivatives of pyridyl-indole based heteroaryl chalcone as potential carbonic anhydrase IX inhibitors and anticancer agents. Eur J Med Chem. 2018;155:13–23.
   PubMed Web of Science ®Google Scholar
• Pontes O, Costa M, Santos F, et al. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment. Eur J Med Chem. 2018;157:101–114.
   PubMed Web of Science ®Google Scholar
• Huang X, Huang R, Wang Z, et al. Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells. Eur J Med Chem. 2018;146:435–450.
   PubMed Web of Science ®Google Scholar
• Singh A, Saha ST, Shanen PS, et al. Azide–alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered isatin–ferrocene, ferrocenylmethoxy-isatin, and isatin-ferrocenylchalcone conjugates: synthesis and antiproliferative evaluation. ACS Omega. 2018;3:1263–1268.
   PubMed Web of Science ®Google Scholar
• Badr G, Gul HI, Yamali C, et al. Curcumin analogue 1,5-bis(4-hydroxy-3-((4-methylpiperazin-1-yl)methyl)phenyl)penta-1,4-dien-3-one mediates growth arrest and apoptosis by targeting the PI3K/AKT/mTOR and PKC-theta signalling pathways in human breast carcinoma cells. Bioorg Chem. 2018;78:46–57.
   PubMed Web of Science ®Google Scholar
• Gul HI, Yamali C, Gunesacar G, et al. Cytotoxicity, apoptosis, and QSAR studies of phenothiazine derived methoxylated chalcones as anticancer drug candidates. Med Chem Res. 2018;27:2366–2378.
   Web of Science ®Google Scholar
• Williams IS, Joshi P, Gatchie L, et al. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Bioorg Med Chem Lett. 2017;27:3683–3687.
   PubMed Web of Science ®Google Scholar
• Ren B, Ablise M, Yang X, et al. Synthesis and biological evaluation of α-methyl-chalcone for anti-cervical cancer activity. Med Chem Res. 2017;26:1871–1883.
   Google Scholar
• YueQiu H, Wang F, Wang X, et al. Design, synthesis, and biological evaluation of chalcone-containing shikonin derivatives as inhibitors of tubulin polymerization. ChemMedChem. 2017;12:399–406.
   PubMed Web of Science ®Google Scholar
• Yamali C, Ozgun DO, Gul HI, et al. Synthesis and structure elucidation of 1-(2,5/3,5-difluorophenyl)-3-(2,3/2,4/2,5/3,4-dimethoxyphenyl)-2-propen-1-ones as anticancer agents. Med Chem Res. 2017;26:2015–2023.
   Web of Science ®Google Scholar
• Lima RS, Perez CN, Da Silva CC, et al. Structure and cytotoxic activity of terpenoid-like chalcones. Arabian J Chem. DOI:10.1016/j.arabjc.2016.02.013.
   Google Scholar
• Singh AK, Saxena G, Dixit S, et al. Synthesis, characterization and biological activities of some Ru(II) complexes with substituted chalcones and their applications as chemotherapeutics against breast cancer. J Mol Struct. 2016;1111:90–99.
   Web of Science ®Google Scholar
• Maoa Z, Zheng X, Qi Y, et al. Synthesis and biological evaluation of novel hybrid compounds between chalcone and piperazine as potential antitumor agents. RSC Adv. 2016. DOI:10.1039/C5RA20197G.
   Google Scholar
• Jayashree BS, Patel HH, Mathew NS, et al. Synthesis of newer piperidinyl chalcones and their anticancer activity in human cancer cell lines. Res Chem Intermed. 2016;42:3673–3688.
   Web of Science ®Google Scholar
• Yamali C, Gul HI, Sakagami H, et al. Synthesis and bioactivities of halogen bearing phenolic chalcones and their corresponding bis Mannich bases. J Enzyme Inhib Med Chem. 2016;31:125–131.
   PubMed Web of Science ®Google Scholar
• Banday AH, Kulkarni VV, Hruby VJ. Design, synthesis, and biological and docking studies of novel epipodophyllotoxin-chalcone hybrids as potential anticancer agents. Med Chem Commun. 2015;6:94–104.
   Web of Science ®Google Scholar
• Wang L, Chen G, Lu X, et al. Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: synthesis, anti-invasive and anti-angiogenic properties. Eur J Med Chem. 2015;89:88–97.
   PubMed Web of Science ®Google Scholar
• Markovic V, Debeljak N, Stanojkovic T, et al. Anthraquinoneechalcone hybrids: synthesis, preliminary antiproliferative evaluation and DNA-interaction studies. Eur J Med Chem. 2015;89:401–410.
   PubMed Web of Science ®Google Scholar
• Shen YN, Lin L, Qiu HY, et al. The design, synthesis, in vitro biological evaluation and molecular modeling of novel benzenesulfonate derivatives bearing chalcone moieties as potent anti-microtubulin polymerization agents. RSC Adv. 2015. DOI:10.1039/C4RA12108B.
   Web of Science ®Google Scholar
• Tugrak M, Yamali C, Sakagami H, et al. Synthesis of mono Mannich bases of 2-(4-hydroxybenzylidene)-2,3-dihydroinden-1-one and evaluation of their cytotoxicities. J Enzyme Inhib Med Chem. 2015. Early Online:1-6. DOI:10.3109/14756366.2015.1070263.
   Web of Science ®Google Scholar
• Chu DTW, Plattner JJ, Katz L. New directions in antibacterial research. J Med Chem. 1996;39:3853–3873.
   PubMed Web of Science ®Google Scholar
• Verhoef J, Fluit A. Surveillance uncovers the smoking gun for resistance emergence. Biochem Pharmacol. 2006;71:1036–1041.
   PubMed Web of Science ®Google Scholar
• Ronat J-B, Kakol J, Khoury MN, et al. Highly drugresistant pathogens implicated in burn associated Bacteremia in an Iraqi burn care unit. PLoS ONE. 2014;9:e101017.
   PubMed Web of Science ®Google Scholar
• Mitscher LA, Pillai SP, Gentry EJ, et al. Multiple drug resistance. Med Res Rev. 1999;19:477–496.
   PubMed Web of Science ®Google Scholar
• Yoneyama H, Katsumata R. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci Biotechnol Biochem. 2006;70:1060–1075.
   PubMed Web of Science ®Google Scholar
• Abbas SY, Sh El-Sharief MAM, Basyouni MW, et al. Thiourea derivatives incorporating a hippuric acid moiety: synthesis and evaluation of antibacterial and antifungal activities. Eur J Med Chem. 2013;64:111–120.
   PubMed Web of Science ®Google Scholar
• Helal MH, Abbas SY, Salem MA, et al. Synthesis and characterization of new types of 2-(6-methoxy-2-naphthyl) propionamide derivatives as potential antibacterial and antifungal agents. Med Chem Res. 2013;22:5598–5609.
   Web of Science ®Google Scholar
• Fluit AC, van der Bruggen JT, Aarestrup FM, et al. Priorities for antibiotic resistance surveillance in Europe. Clin Microbiol Infect. 2006;12:410–417.
   PubMed Web of Science ®Google Scholar
• Alcaraz LE, Blanco SE, Puig ON, et al. Antibacterial activity of flavonoids against methicillin-resistant Staphylococcus aureus strains. J Theor Biol. 2008;205:231–240.
   Google Scholar
• Lahtchev KL, Batovska DI, Parushev SP, et al. Antifungal activity of chalcones: A mechanistic study using various yeast strains. Eur J Med Chem. 2008;43:2220–2228.
   PubMed Web of Science ®Google Scholar
• Liu YT, Sheng J, Yin DW, et al. Ferrocenyl chalcone-based Schiff bases and their metal complexes: highlyefficient, solvent-free synthesis, characterization, biological research. J Organomet Chem. 2018;856:27–33.
   Web of Science ®Google Scholar
• Seidani TB, Keivanloo A, Kaboudin B, et al. Regioselective synthesis of 2,3-disubstituted 1-alkyl pyrrolo[2,3-b]quinoxalines through palladium-catalyzed Heck reaction of chalcones and evaluation of their anti-bacterial activities. Tetrahedron. 2018;74:2350–2358.
   Web of Science ®Google Scholar
• Lal K, Yadav P, Kumar A, et al. Design, synthesis, characterization, antimicrobial evaluation and molecular modeling studies of some dehydroacetic acid-chalcone-1,2,3-triazole hybrids. Bioorg Chem. 2018;77:236–244.
   PubMed Web of Science ®Google Scholar
• Yadav P, Lal P, Kumar L, et al. Synthesis, crystal structure and antimicrobial potential of some fluorinated chalcone-1,2,3-triazole conjugates. Eur J Med Chem. 2018;155:263–274.
   PubMed Web of Science ®Google Scholar
• Vanangamudi G, Subramanian M, Thirunarayanan G. Synthesis, spectral linearity, antimicrobial, antioxidant and insect antifeedant activities of some 2,5-dimethyl-3-thienyl chalcones. Arabian J Chem. 2017;10:S1254–S1266.
   Web of Science ®Google Scholar
• Prabhakar V, Babu KS, Ravindranath LK, et al. Design and facile synthesis of 2H-Chromene halcone derivatives as anti-microbial agents. Heterocycl Lett. 2016;6:687–699.
   Web of Science ®Google Scholar
• Chlupacova MK, Tyllova VV, Finkova LR, et al. Novel halogenated pyrazine-based chalcones as potential antimicrobial drugs. Molecules. 2016;21:1421.
   Web of Science ®Google Scholar
• Wei ZY, Chi KQ, Yu ZK, et al. Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. Bioorg Med Chem Lett. 2016;26:5920–5925.
   PubMed Web of Science ®Google Scholar
• Muskinja J, Burmudzija A, Ratkovic Z, et al. Ferrocenyl chalcones with O-alkylated vanillins: synthesis, spectral characterization, microbiological evaluation, and single-crystal X-ray analysis. Med Chem Res. 2016;25:1744–1753.
   Web of Science ®Google Scholar
• Ashok D, Ravi S, Ganesh A, et al. Microwave-assisted synthesis and biological evaluation of carbazole-based chalcones, aurones and flavones. Med Chem Res. 2016;25:909–922.
   Web of Science ®Google Scholar
• Boopathy M, Subramanian K. Preparation of polycyclic pendant chalcone moiety based antimicrobial polyacrylamides. Adv Polym Technol. 2017;36:21606.
   Web of Science ®Google Scholar
• Prasath R, Bhavana P, Sarveswari S, et al. Efficient ultrasound-assisted synthesis, spectroscopic, crystallographic and biological investigations of pyrazole-appended quinolinyl chalcones. J Mol Struct. 2015;1081:201–210.
   Web of Science ®Google Scholar
• Hamada NMM, Abdo NYM. Synthesis, characterization, antimicrobial screening and free-radical scavenging activity of some novel substituted pyrazoles. Molecules. 2015;20:10468–10486.
   PubMed Web of Science ®Google Scholar
• Gaugler J, James B, Johnson T, et al. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12:459–509.
   PubMedGoogle Scholar
• Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314:777–778.
   PubMed Web of Science ®Google Scholar
• von Strauss E, Viitanen M, De Ronchi D, et al. Aging and the occurrence of dementia findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999;56:587–592.
   PubMedGoogle Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2018;2018(14):367–429.
   Google Scholar
• Dementia fact sheet. World Health Organisation; Dec 2017 [cited 2018 Oct 1]. Available from: http://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42 (43)and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13:45–53.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann N Y Acad Sci. 2000;920:321–327.
   PubMed Web of Science ®Google Scholar
• Shen LL, Liu GX, Tang Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol Sin. 2007;28:2053–2063.
   PubMed Web of Science ®Google Scholar
• Lu C, Zhou Q, Yan J, et al. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease. Eur J Med Chem. 2013;62:745–753.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer’s disease: targeting the sholinergic system. Curr Neuropharmacol. 2016;14:101–115.
   PubMed Web of Science ®Google Scholar
• Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. Biomed Rep. 2016;4:519–522.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Scapagnini G, Candore G, et al. Immuneinflammatory responses and oxidative stress in Alzheimer’s disease: therapeutic implications. Curr Pharm Des. 2010;16:684–691.
   PubMed Web of Science ®Google Scholar
• Heneka MT, O’Banion MK, Terwel D, et al. Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm. 2010;117:919–947.
   PubMed Web of Science ®Google Scholar
• Oakley H, Cole SL, Logan S, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129–10140.
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci. 2007;8:499–509.
   PubMed Web of Science ®Google Scholar
• Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis. 2013;33:277–281.
   PubMed Web of Science ®Google Scholar
• Robert A, Liu Y, Nguyen M, et al. Regulation of c and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer’s disease. Acc Chem Res. 2015;48:1332–1339.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 1993;621:35–49.
   PubMed Web of Science ®Google Scholar
• Khan HA, Sher M, Maharvi M, et al. Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J Enzyme Inhib Med Chem. 2005;20:41–47.
   PubMed Web of Science ®Google Scholar
• Cui M, Ono M, Kimura H, et al. Synthesis and biological evaluation of indole-chalcone derivatives as β-amyloid imaging probe. Bioorg Med Chem Lett. 2011;21:980–982.
   PubMedGoogle Scholar
• Ono M, Ikeoka R, Watanabe H, et al. Synthesis and evaluation of novel chalcone derivatives with 99mTc/Re complexes as potential probes for detection of β-amyloid plaques. ACS Chem Neurosci. 2010;1:598–607.
   PubMed Web of Science ®Google Scholar
• Ono M, Watanabe R, Kawashima H, et al. Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of β-amyloid plaques in Alzheimer’s disease. J Med Chem. 2009;52:6394–6401.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Tian Y, et al. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors. Bioorg Med Chem. 2017;25:360–371.
   PubMed Web of Science ®Google Scholar
• Fosso MY, LeVine H, Green KD, et al. Effects of structural modifications on the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones. Org Biomol Chem. 2015;13:9418–9426.
   PubMed Web of Science ®Google Scholar
• Khoshneviszadeh M, Ghahremani MH, Foroumadi A, et al. Design, synthesis and biological evaluation of novel anti-cytokine 1, 2, 4-triazine derivatives. Bioorg Med Chem. 2013;21:6708–6717.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang X, Jia L, et al. Inhibiting DNA Methylation by 5-Aza-2’-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. Endocrinology. 2014;155:4925–4938.
   PubMed Web of Science ®Google Scholar
• Ansari N, Khodagholi F, Ramin M, et al. Inhibition of LPS-induced apoptosis in differentiated-PC12 cells by new triazine derivatives through NF-kappaB-mediated suppression of COX-2. Neurochem Int. 2010;57:958–968.
   PubMed Web of Science ®Google Scholar
• Miyagawa T, Fujita T, Ouhara K, et al. Irsogladine maleate regulates the inflammatory related genes in human gingival epithelial cells stimulated by Aggregatibacter actinomycetemcomitans. Int Immunopharmacol. 2013;15:340–347.
   PubMed Web of Science ®Google Scholar
• Moo-Huchin VM, Moo-Huchin MI, Estrada-Leon RJ, et al. Antioxidant compounds, antioxidant activity and phenolic content in peel from three tropical fruits from Yucatan, Mexico. Food Chem. 2015;166:17–22.
   PubMed Web of Science ®Google Scholar
• Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Pnas. 2001;98:14583–14588.
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387–437.
   PubMed Web of Science ®Google Scholar
• Moore ND. In search of an ideal analgesic for common acute pain. Acute Pain. 2009;11:129–137.
   Google Scholar
• Dannhardt G, Laufer S. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr Med Chem. 2000;7:1101–1112.
   PubMed Web of Science ®Google Scholar
• Labiba MB, Sharkawib SMZ, El-Dalyc M. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: antiinflammatory, analgesic activities and docking study. Bioorg Chem. 2018;80:70–80.
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez F, Sanchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol. 2015;45:679–686.
   PubMed Web of Science ®Google Scholar
• Domiati S, El-Mallah A, Ghoneim A, et al. Evaluation of anti-inflammatory, analgesic activities, and side effects of some pyrazole derivatives. Inflammopharmacology. 2016;24:163–172.
   PubMed Web of Science ®Google Scholar
• Kontogiorgis C, Mantzanidou M, Hadjipavlou LD. Chalcones and their potential role in inflammation. Mini Rev Med Chem. 2008;8:1224–1242.
   PubMed Web of Science ®Google Scholar
• Bukhari SNA, Jantan I, Jasamai M. Anti-inflammatory trends of 1, 3- diphenyl-2-propen-1-one derivatives. Mini Rev Med Chem. 2013;13:87–94.
   PubMed Web of Science ®Google Scholar
• Middleton E, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol. 1992;43:1167–1179.
   PubMed Web of Science ®Google Scholar
• Jung JC, Lee Y, Min D, et al. Practical synthesis of chalcone derivatives and their biological activities. Molecules. 2017;22:1872.
   Google Scholar
• Abdellatif KRA, Elshemy HAH, Salama SA, et al. Synthesis, characterization and biological evaluation of novel 4′-fluoro-2′-hydroxy-chalcone derivatives as antioxidant, anti-inflammatory and analgesic agents. J Enzyme Inhib Med Chem. 2015;30:484–491.
   PubMed Web of Science ®Google Scholar
• Chen W, Ge X, Xu F, et al. Design, synthesis and biological evaluation of paralleled Aza resveratrol–chalcone compounds as potential anti-inflammatory agents for the treatment of acute lung injury. Bioorg Med Chem Lett. 2015;25:2998–3004.
   PubMed Web of Science ®Google Scholar
• Bukhari SNA, Zhang X, Jantan I, et al. Synthesis, molecular modeling, and biological evaluation of novel 1, 3-diphenyl-2-propen-1-one based pyrazolines as anti-inflammatory agents. Chem Biol Drug Des. 2015;85:729–742.
   PubMed Web of Science ®Google Scholar
• Rani A, Singh A, Gut J, et al. Microwave-promoted facile access to 4-aminoquinolinephthalimides: synthesis and anti-plasmodial evaluation. Eur J Med Chem. 2018;143:150–156.
   PubMed Web of Science ®Google Scholar
• World-malaria-report-2017. [cited 2019 Jan 14]. Available from: http://www.who.int/malaria/publications/world-malariareport-2017/en/
   Google Scholar
• Kalaria PN, Karad SC, Raval DK. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. Eur J Med Chem. 2018;158:917–936.
   PubMed Web of Science ®Google Scholar
• Kumari A, Manvika Karnatak M, Davinder Singh D, et al. Current scenario of artemisinin and its analogues for antimalarial activity. Eur J Med Chem. 2019;163:804–829.
   PubMed Web of Science ®Google Scholar
• Ecker A, Lehane AM, Clain J, et al. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 2012;28:504–514.
   PubMed Web of Science ®Google Scholar
• Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–871.
   PubMed Web of Science ®Google Scholar
• Gutteridge CE, Nichols DA, Curtis SM, et al. In vitro and in vivo efficacy and in vitro metabolism of 1-phenyl-3-aryl-2-propen-1-ones against Plasmodium falciparum. Bioorg Med Chem Lett. 2006;16:5682–5686.
   PubMed Web of Science ®Google Scholar
• Liu M, Wilairat P, Go ML. Antimalarial alkoxylated and hydroxylated chalcones [corrected]: structure-activity relationship analysis. J Med Chem. 2001;44:4443–4452.
   PubMed Web of Science ®Google Scholar
• Chen M, Theander TG, Christensen SB, et al. a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother. 1994;38:1470–1475.
   PubMed Web of Science ®Google Scholar
• Chen M, Christensen SB, Zhai L, et al. The novel oxygenated chalcone, 2,4-dimethoxy-4’-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis. 1997;176:1327–1333.
   PubMed Web of Science ®Google Scholar
• Sriwilaijaroen N, Liu M, Go ML, et al. Plasmepsin II inhibitory activity of alkoxylated and hydroxylated chalcones. Southeast Asian J Trop Med Public Health. 2006;37:607–612.
   PubMedGoogle Scholar
• Dominguez JN, Charris JE, Lobo G, et al. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur J Med Chem. 2001;36:555–560.
   PubMed Web of Science ®Google Scholar
• Go ML, Liu M, Wilairat P, et al. Antiplasmodial chalcones inhibit sorbitol-induced hemolysis of plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother. 2004;48:3241–3245.
   PubMed Web of Science ®Google Scholar
• Singh A, Gut J, Rosenthal PJ, et al. 4-Aminoquinoline-ferrocenyl-chalcone conjugates: synthesis and anti-plasmodial evaluation. Eur J Med Chem. 2017;125:269–277.
   PubMed Web of Science ®Google Scholar
• Singh A, Rani A, Gut J, et al. Piperazine-linked 4-aminoquinoline-chalcone/ferrocenyl-chalcone conjugates: synthesis and antiplasmodial evaluation. Chem Biol Drug Des. 2017;90:590–595.
   PubMed Web of Science ®Google Scholar
• Kumar S, Saini A, Gut J. et al. 4-Aminoquinoline-chalcone/-N-acetylpyrazoline conjugates: synthesis and antiplasmodial evaluation. Eur J Med Chem. 2017;29(138):993–1001.
   Google Scholar
• Smit FJ, Bezuidenhout JJ, Bezuidenhout CC, et al. Synthesis and in vitro biological activities of ferrocenyl-chalcone Amides. Med Chem Res. 2016;25:568–584.
   Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. Current Opin Clin Nutr Metab Care. 2014;17:40–44.
   PubMed Web of Science ®Google Scholar
• Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev. 1994;52:253–265.
   PubMed Web of Science ®Google Scholar
• Meo FD, Lemaur V, Cornil J, et al. Free radical scavenging by natural polyphenols: atom versus electron transfer. J Phys Chem A. 2013;117:2082–2092.
   PubMedGoogle Scholar
• Narsinghani T, Sharma MC, Bhargav S. Synthesis, docking studies and antioxidant activity of some chalcone and aurone derivatives. Med Chem Res. 2013;22:4059–4068.
   Web of Science ®Google Scholar
• Niu G, Wang W, Li J, et al. A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: design, synthesis, biological evaluation and molecular docking studies. Eur J Med Chem. 2017;138:212–220.
   PubMed Web of Science ®Google Scholar
• Cheng JH, Hung CF, Yang SC, et al. Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 2′,5′-dialkoxylchalcones as cancer chemopreventive agents. Bioorg Med Chem. 2008;16:7270–7276.
   PubMed Web of Science ®Google Scholar
• El Sayed Aly MR, Abd El Razek Fodah HH, Saleh SY. Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes. Eur J Med Chem. 2014;76:517–530.
   PubMed Web of Science ®Google Scholar
• Tajammal A, Batool M, Ramzan A, et al. Synthesis, antihyperglycemic activity and computational studies of antioxidant chalcones and flavanones derived from 2,5 dihydroxyacetophenone. J Mol Struct. 2017;1148:512–520.
   Web of Science ®Google Scholar
• Ahmad MR, Sastry VG, Bano N, et al. Synthesis of novel chalcone derivatives by conventional and microwave irradiation methods and their pharmacological activities. Arabian J Chem. 2016;9:S931–S935.
   Web of Science ®Google Scholar
• Rani A, Viljoen A, Sumanjit, et al. Microwave-assisted highly efficient route to 4-aminoquinoline-phthalimide conjugates: synthesis and anti-tubercular evaluation. ChemistrySelect. 2017;2:10782–10785.
   Web of Science ®Google Scholar
• World Health Organization (WHO). WHO Global Tuberculosis Report 2018. Geneve (Switzerland): WHO; 2018. Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• Revised National Tuberculosis Control Program. Training manual on intensified TB/HIV package. New Delhi: Ministry of Health and Family Welfare; 2017.
   Google Scholar
• Lu X, Tang J, Cui S, et al. Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: design, synthesis and evaluation of anti-tubercular activity. Eur J Med Chem. 2017;125:41–48.
   PubMed Web of Science ®Google Scholar
• Chetty S, Ramesh M, Pillay AS, et al. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett. 2017;27:370–386.
   PubMed Web of Science ®Google Scholar
• Javaid A, Ahmad N, Khan A, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J. 2017;49:1601967.
   PubMed Web of Science ®Google Scholar
• Schito M, Maeurer M, Kim P, et al. Translating the tuberculosis research agenda: much accomplished, but much more to be done. Clin Infect Dis. 2015;3:95–101.
   Google Scholar
• WHO treatment guidelines for drug-resistant tuberculosis (2016 update). [cited 2019 Jan 14]. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/
   Google Scholar
• Garcia A, Bocanegra-Garcia V, Palma-Nicolas JP, et al. Recent advances in antitubercular natural products. Eur J Med Chem. 2012;49:1–23.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Thakur JP, Chanda D, et al. Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents. Bioorg Med Chem Lett. 2013;23:1322–1325.
   PubMed Web of Science ®Google Scholar
• Solankee A, Kapadia K, Ciric A, et al. Synthesis of some new S-triazine based chalcones and their derivatives as potent antimicrobial agents. Eur J Med Chem. 2010;45:510–518.
   PubMed Web of Science ®Google Scholar
• Tran TD, Nguyen TT, Do TH, et al. Synthesis and antibacterial activity of some heterocyclic chalcone analogues alone and in combination with antibiotics. Molecules. 2012;17:6684–6696.
   PubMed Web of Science ®Google Scholar
• Fliur M, Veaceslav B, Serghei P, et al. Chalcone scaffold based antimycobacterial agents. Med Chem. 2014;4:487–493.
   Google Scholar
• Sivakumar PM, Seenivasan SP, Kumar V, et al. Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives. Bioorg Med Chem Lett. 2007;17:1695–1700.
   PubMed Web of Science ®Google Scholar
• Hans RH, Guantai EM, Lategan C, et al. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorg Med Chem Lett. 2010;20:942–944.
   PubMed Web of Science ®Google Scholar
• Chiaradia LD, Mascarello A, Purificacao M, et al. Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med Chem Lett. 2008;18:6227–6230.
   PubMed Web of Science ®Google Scholar
• Kanokmedhakul S, Kanokmedhakul K, Phonkerd N, et al. Antimycobacterial anthraquinone-chromanone compound and diketopiperazine alkaloid from the fungus Chaetomium globosum KMITL-N0802. Planta Med. 2002;68:834–836.
   PubMed Web of Science ®Google Scholar
• Friis-Moller A, Chen M, Fuursted K, et al. In vitro antimycobacterial and antilegionella activity of licochalcone a from Chinese licorice roots. Planta Med. 2002;68:416–419.
   PubMed Web of Science ®Google Scholar
• Macaev F, Boldescu V, Pogrebnoi S, et al. Chalcone scaffold based antimycobacterial agents. Med chem. 2014;4:487–493.
   Google Scholar
• Dobchev DA, Pillai GG, Karelson M. In silico machine learning methods in drug development. Curr Top Med Chem. 2014;14:1913–1922.
   PubMed Web of Science ®Google Scholar
• Caldwell GW. In silico tools used for compound selection during target-based drug discovery and development. Expert Opin Drug Discov. 2015;10:1913–1922.
   Web of Science ®Google Scholar
• Desai V, Desai S, Gaonkar SN, et al. Novel quinoxalinyl chalcone hybrid scaffolds as enoyl ACP reductase inhibitors: synthesis, molecular docking and biological evaluation. Bioorg Med Chem Lett. 2017;27:2174–2180.
   PubMedGoogle Scholar
• Santivanez-Veliz M, Perez-Silanes S, Torres E, et al. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. Bioorg Med Chem Lett. 2016;26:2188–2193.
   PubMed Web of Science ®Google Scholar
• Joshi SD, Dixit SR, Kirankumar MN, et al. Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties. Eur J Med Chem. 2016;107:133–152.
   PubMed Web of Science ®Google Scholar